Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Anti H1s of the third generation, of which the first was Terfenadine, possess not only blocking effects on H1 receptors to histamine, but also have a "cromone-like" action on the membranes of cells that have been, or not, activated by specific stimuli (antigens). They act on the early phase of immediate hypersensitivity. These anti H1s of the new generation also have wider indications: asthma, perennial or pollen rhinitis, dermatoses such as urticaria and atopic dermatitis. Their tolerance has been remarkably improved with regard to the central effect (very reduced), such as absence of an atropine effect.
 ...
PMID:[The rebirth of the H1-antagonists]. 137 13

H1-type antihistamines are considered the therapeutic agents of choice for treating urticaria and angioedema. The use of traditional H1 antihistamines is limited by their side effects. In recent years low-sedating H1 antihistamines with reduced sedative and anticholinergic side effects have become popular choices for the treatment of urticaria and angioedema. Terfenadine and astemizole are currently available in the United States, and cetirizine and loratadine, currently under review at the Food and Drug Administration, are available in other countries. Terfenadine, cetirizine, and loratadine achieve rapid peak plasma concentrations in 1 to 2 hours, whereas astemizole has a slow onset of action. In double-blind, placebo-controlled studies of chronic idiopathic urticaria, low-sedating H1 antihistamines were more effective than placebo. The choice of a particular low-sedating H1 antihistamine depends on pharmacokinetic considerations and frequency of administration.
 ...
PMID:Treatment of urticaria and angioedema: low-sedating H1-type antihistamines. 167 11

Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity. Its safety and efficacy were evaluated in a 28-day study conducted in patients with chronic idiopathic urticaria. Patients were randomly assigned to one of three treatment groups (loratadine, 10 mg OD; terfenadine, 60 mg BID; or placebo). Evaluation of efficacy included weekly assessments of the individual disease signs and symptoms, the overall disease condition, and therapeutic response to treatment. Throughout the 28-day treatment period progressive improvement was observed in the loratadine and terfenadine treatment groups; however, at each evaluation, loratadine was significantly more effective than placebo (P less than .01) and clinically more effective than terfenadine in reducing disease signs and symptoms. Terfenadine was significantly more effective than placebo at day 7 and endpoint (last valid visit). The overall therapeutic response at the endpoint of treatment was rated as marked or complete relief of symptoms in 64%, 52%, and 25% of the patients in the loratadine, terfenadine, and placebo treatment groups, respectively. Loratadine was well tolerated and comparable to terfenadine and placebo in incidence of adverse experiences. Sedation was reported in one patient each in the terfenadine and placebo treatment groups and an anticholinergic side effect (dry mouth) in one terfenadine-treated patient. No sedative or anticholinergic side effects were observed in patients receiving loratadine. We concluded that loratadine, 10 mg, once daily is a safe and effective treatment for symptomatic relief of chronic idiopathic urticaria.
 ...
PMID:Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. 196 19

Solar urticaria is a rare photodermatosis, but it is extremely incapacitating and therapy is usually ineffective. Three patients who took a daily dose of 240 mg terfenadine were able to be normally exposed to sunlight. This efficacy was confirmed by photobiological tests. The minimal dose necessary to induce urticaria was increased at least three times. These results confirming recently published ones. Terfenadine at 240 mg per day seems to be the treatment of choice for solar urticaria because of its efficacy and excellent tolerance-especially as there is no sedative effect.
 ...
PMID:[Treatment of solar urticaria: advantage of terfenadine]. 256 1

Urticaria is a rather common, often vexing skin disease, characterized by evanescent, pruritic, erythematous wheals, and sometimes by giant hives (angioedema). The cause of chronic urticaria remains unknown in 75 to 80 percent of the cases. Its pathogenesis is related to the activation of tissue mast cells by many immunologic or non-immunologic mechanisms, resulting in a release of biologically active products. The therapeutic possibilities in practice are discussed. Non-sedative antihistaminic drugs of the H1 type (Terfenadine, Astemizole, Loratidine and Cetirizine) are the main stay in the treatment of urticaria. In case of failure the sedative non-selective antihistaminics from the old generation are used. Particular emphasis is given the possibilities to combining various antiallergic drugs. The combination of a H1 and H1 antihistamine can be effective in individual patients.
 ...
PMID:[Therapy of acute and chronic urticaria and of Quincke's edema]. 256 13

The ability of drugs to inhibit histamine-induced wheals has been used frequently as a pharmacodynamic index of clinical efficacy. Host response using this model can be predictive of clinical response in atopic diseases such as allergic rhinitis and urticaria. Terfenadine is a widely used nonsedating antihistamine currently approved for use at a dosage of 60 mg every 12 hours. Our clinical trial was designed to determine whether higher dosages of this agent were associated with amplified efficacy in suppressing the wheal response to intradermal histamine phosphate. Twenty-six healthy male Caucasian volunteers were randomized in a double-blind crossover fashion to receive terfenadine 60 mg every 12 hours, 120 mg each day, 120 mg every 12 hours, and placebo. Each dose was given orally for three days followed by a 6-day washout period. Histamine was administered intradermally one hour prior to dosing for baseline measurements. Histamine was given at defined intervals after treatment or placebo on days 1 (acute dosing) and 3 (steady state), and the percent inhibition of histamine-induced wheal area as compared with baseline was determined. Subjects receiving all three active doses exhibited significant wheal inhibition compared with placebo on days 1 and 3 (P less than or equal to .01). Subjects receiving the 60 mg every 12 hours and the 120 mg each day dosages exhibited roughly equivalent mean wheal suppression over the 24-hour period of each testing day (54% versus 60%, respectively, on day 1 and 62% versus 63%, respectively, on day 3, no significant differences).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Evaluation of inhibition of wheal response to histamine by multiple doses of terfenadine. 257 53

Terfenadine, an anti-H1-selective antihistaminic drug has been used in an experimental clinical study. The effectiveness and tolerance of the compound in the treatment of pruritic dermatitis such as urticaria, atopic dermatitis and topical dermatitis, have been evaluated. Terfenadine, administered in 120 mg tablets in a single daily dose in 30 patients demonstrated a fully satisfactory therapeutic activity and reliability of use.
 ...
PMID:[Treatment of histamine-dependent allergic dermatoses with a 120-mg terfenadine tablet once a day]. 257 23

To investigate the mechanisms of non-immunologic contact urticaria (NICU), the effect of 120 mg of terfenadine (H1-antagonist) on contact reactions to methyl nicotinate, diethyl fumarate, benzoic acid, cinnamic acid, cinnamic aldehyde and dimethyl sulfoxide was studied in 20 subjects. Erythema and edema were observed visually, and the changes in the skin blood flow were monitored with laser-Doppler flowmetry. Terfenadine did not have any significant inhibitory effect on erythema or edema from 6 contact urticariants tested, but it inhibited erythema and edema of prick test reactions to histamine. Non-specific histamine release from mast cells does not seem to be the mechanism of NICU from these substances.
 ...
PMID:Terfenadine does not inhibit non-immunologic contact urticaria. 288 50

The efficacy of terfenadine, a nonsedating H1 antihistamine, in the management of chronic idiopathic urticaria was compared with chlorpheniramine and placebo in a parallel multicenter trial. Subjects with symptoms of hives for 3 days per week for at least 6 weeks were initially screened and admitted if no identifiable cause for symptoms could be determined. Patients entered a single-blind placebo period, and if hives of moderate severity were present for at least 3 days during the week, they were randomly assigned in a double-blind fashion to take terfenadine, 60 mg twice daily, chlorpheniramine, 4 mg three times a day, or placebo for 6 weeks. Data were analyzed for 122 patients. Those patients receiving both active treatments noted significant improvement in symptoms: pruritus, redness, number of hives, and waking hours during which hives were present, at the end of the first day of therapy. Symptom control by terfenadine was statistically superior to placebo during all 6 weeks, as rated by both patients and investigators. However, statistical significance was not achieved for chlorpheniramine at all observation points. Diphenhydramine was permitted as a relief medication for refractory symptoms and was taken by 52% of subjects receiving placebo, 26% taking chlorpheniramine, and only 9% of patients who were receiving terfenadine. In addition to providing superior symptom control, terfenadine caused less drowsiness and fatigue than chlorpheniramine. Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria.
 ...
PMID:Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. 312 20

Terfenadine, a potent and non-sedative antihistamine, was shown to be effective in chronic idiopathic urticaria in a double-blind crossover placebo controlled trial. An oral twice daily 60 mg dose of terfenadine was given and itch and wheal parameters were assessed daily. Despite the overall effectiveness of terfenadine, a variable response was noted which was similar to that shown in previous studies with other antihistamines.
 ...
PMID:Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study. 393 49


1 2 Next >>